Maxidex (dexamethasone eye drops, suspension)
/ Novartis, Harrow Health
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
194
Go to page
1
2
3
4
5
6
7
8
December 05, 2025
Acute posterior multifocal placoid pigment epitheliopathy complicated by a stroke, leading to the diagnoses of lupus anticoagulant and hypercysteinemia.
(PubMed, J Fr Ophtalmol)
- "APMPPE is a well-established disease, and neurological complications are rare. Cerebral vasculitis and strokes are the most commonly reported neurological lesions. The search for antiphospholipid syndrome and hypercysteinemia in the first-line work-up of APMPPE should be considered."
Journal • Cardiovascular • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Ocular Inflammation • Ophthalmology • Uveitis • Vasculitis
November 17, 2025
Engineering Mixed Micelle-Loaded Contact Lenses for Sustained Ocular Delivery of Dexamethasone: In Vitro and In Vivo Studies.
(PubMed, ACS Appl Bio Mater)
- "Conventional dexamethasone eye drops suffer from poor ocular bioavailability due to rapid tear turnover and limited corneal residence, necessitating frequent dosing and posing challenges in chronic ocular therapies...In conclusion, this dual-surfactant micelle platform markedly enhances the therapeutic potential of drug-eluting contact lenses, offering a safe, sustained, and patient-compliant alternative for managing ocular inflammation. These findings support further clinical translation of micelle-integrated lenses as next-generation ocular drug delivery systems."
Journal • Preclinical • Inflammation • Ocular Inflammation • IL6
October 16, 2025
COHOST: Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy
(clinicaltrials.gov)
- P1/2 | N=20 | Not yet recruiting | Sponsor: University of Nebraska | Trial primary completion date: Jan 2027 ➔ Jul 2027
Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease
October 08, 2025
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
(clinicaltrials.gov)
- P2 | N=236 | Active, not recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Aug 2025 ➔ Aug 2026
Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation
October 03, 2025
Treating retinopathy of prematurity with dexamethasone eye drops: a difference-in-differences study in Sweden using register data.
(PubMed, Ophthalmology)
- "In this population of infants with severe ROP, the introduction of dexamethasone eye drops was associated with a significant reduction in the proportion of infants requiring traditional ROP treatments. A timely administration of low-dose dexamethasone eye drops may serve as a simple, cost-effective, and noninvasive intervention to reduce one of the leading causes of severe visual impairment worldwide. Further studies are needed to confirm our findings."
Journal • Retinal Disorders • Retinopathy of Prematurity
September 26, 2025
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
(clinicaltrials.gov)
- P2 | N=46 | Active, not recruiting | Sponsor: Dana-Farber Cancer Institute | Trial completion date: Jun 2025 ➔ Oct 2025
Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology
September 25, 2025
The efficacy of combined povidone-iodine 1% and dexamethasone 0.08% prepared eye drops in treating post-viral corneal subepithelial infiltrates.
(PubMed, Indian J Ophthalmol)
- "Combined povidone-iodine 1% and dexamethasone 0.08% eye drops offer superior improvement in SEIs, BCVA, and symptom relief, with lower recurrence compared to individual treatments. These findings suggest a potential synergistic effect of combined treatment in managing SEIs."
Clinical • Journal • Allergy • Conjunctivitis • Dry Eye Disease • Endocrine Disorders • Immunology • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology
July 31, 2025
Acute Central Toxic Keratopathy Induced by Exposure to Chinese Herbal Medicine Fluid for Verruca Plana: A Case Report.
(PubMed, Case Rep Ophthalmol Med)
- "Thus, tobramycin dexamethasone eye drops and artificial tears were prescribed for her, which proved effective. Her clinical symptoms and signs were both resolved after steroid treatment and remained stable at the 1-month follow-up. Acute central toxic keratopathy could occur after exposure to Chinese herbal medicine fluid, and enhanced topical steroid treatment worked well for alleviating inflammation and reducing corneal opacity."
Journal • Inflammation • Ophthalmology • Pain
July 25, 2025
Tacrolimus eye drops treatment for recurrent exposure of the Ahmed glaucoma valve tube.
(PubMed, Eur J Med Res)
- "Treatment with 0.1% tacrolimus eye drops demonstrated satisfactory results in managing recurrent exposure following allogeneic scleral patch graft coverage and autologous scleral tunnel repair, suggesting its potential as an effective alternative to conventional treatments."
Journal • Glaucoma • Ophthalmology • Transplantation
June 27, 2025
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
(clinicaltrials.gov)
- P2 | N=70 | Completed | Sponsor: Emory University | Active, not recruiting ➔ Completed
Trial completion • Hematological Malignancies • Multiple Myeloma • Oncology
June 23, 2025
Comparison of Tobramycin-Dexamethasone Combination Eyedrop Versus Artificial Tear Eyedrop for the Management of Presumed Viral Epidemic Conjunctivitis: A Randomized Treatment Trial.
(PubMed, Curr Eye Res)
- "To compare the efficacy and safety of one-time povidone-iodine (PovI) administration followed by a course of tobramycin-dexamethasone eye drops versus artificial tears in acute viral conjunctivitis (AVC). A course of tobramycin-dexamethasone combination eyedrops after PovI may lead to early symptomatic relief, but recovery was similar to artificial tears by day 7. No significant/sight-threatening complications were observed in any groups."
Journal • Conjunctivitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Pain
June 14, 2025
Subperiosteal abscess of the orbit: case presentation
(SOE 2025)
- "The patient was prescribed Amoxicillin 1000mg twice daily, Ibuprofen 400mg twice daily, Dexamethasone eye drops every two hours, Tobramycin eye drops every two hours.The consilium was held... Orbital complications of acute rhinosinusitis are rare but potentially severe. Rapid diagnostic imaging and urgent endoscopic decompression of the abscess prevent permanent loss of vision and further defects of neurological character. endoscopic access should be the first choice in surgical treatment."
Clinical • Ophthalmology
May 09, 2025
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
(clinicaltrials.gov)
- P1/2 | N=37 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Jan 2027 ➔ Mar 2025
Trial completion • Trial completion date • Tumor mutational burden • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
April 10, 2025
Steroid-Induced Diabetes: When Ocular Treatment Becomes a Metabolic Threat
(ESPE-ESE 2025)
- "We report a case of diabetes induced by dexamethasone eye drops in a 64-year-old patient admitted for the management of nodular prurigo...Healthcare providers should remain vigilant for this potential complication, especially in patients with long-term use. Regular monitoring of blood glucose and timely intervention can prevent long- term complications."
Diabetes • Fatigue • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Ocular Inflammation • Ophthalmology • Prurigo Nodularis • Type 2 Diabetes Mellitus • Uveitis
April 29, 2025
Evaluation of timed dexamethasone eye drops to prevent proliferative retinopathy of prematurity: a study protocol for a randomized intervention, multi-centre, double-blinded trial (DROPROP).
(PubMed, BMC Pediatr)
- P1 | "Timely administration of dexamethasone eye drops may prevent severe ROP from progressing to Type 1 ROP, which requires treatment. This study aims to assess the efficacy and safety of dexamethasone intervention to support its clinical use and national guidelines."
Journal • Ophthalmology • Retinal Disorders • Retinopathy of Prematurity • Strabismus
April 17, 2025
Iatrogenic Cushing Syndrome and Secondary Adrenal Insufficiency in a Child due to Topical Ocular Corticosteroids: A Case Report.
(PubMed, Case Rep Ophthalmol)
- "An 11-year-old girl was referred to our ocular inflammation department due to idiopathic, chronic, non-hypertensive, non-granulomatous bilateral anterior uveitis, treated with topical dexamethasone (eye drops, 1 mg/mL) for 1 year...She was treated with methotrexate (15 mg/week, orally), and the topical corticosteroid regimen was progressively tapered and discontinued after 3 months...Although rare, ophthalmologists must be aware of ICS and SAI and prioritize using the least potent corticosteroid for the shortest duration necessary. Additionally, clinicians should avoid abrupt cessation of long-term corticosteroid therapy as this can precipitate an adrenal crisis in the presence of adrenal insufficiency."
Journal • Cushing’s Disease • Endocrine Disorders • Inflammation • Nephrology • Ocular Inflammation • Ophthalmology • Pediatrics • Renal Disease • Uveitis
March 29, 2025
Stenotrophomonas maltophilia endogenous endophthalmitis in an immunocompetent eye in Australia.
(PubMed, BMC Ophthalmol)
- "S. maltophilia-associated EE is a rare clinical condition, especially in the absence of systemic symptoms. Despite the poor prognosis typically associated with endophthalmitis, this case resulted in a relatively good visual outcome (BCVA 6/18). This report highlights the necessity for further research to elucidate the epidemiology, risk factors, and optimal management strategies for this rare ocular condition."
Journal • Hematological Disorders • Infectious Disease • Inflammation • Mood Disorders • Neutropenia • Ocular Infections • Ocular Inflammation • Ophthalmology • Pain • Retinal Disorders
March 26, 2025
An Accessible Rabbit Model of Meibomian Gland Dysfunction Induced with Complete Freund's Adjuvant for Anti-Inflammatory Treatment Evaluation
(ARVO 2025)
- "The rabbits were divided into three groups: control (n=10), induced + saline eye drop treated (n=10), and induced + 0.1%dexamethasone eye drop treated (n=10)...Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."
Clinical • Preclinical • Ocular Inflammation • Ophthalmology
March 11, 2025
Topical tacrolimus versus dexamethasone in managing shield ulcer of vernal keratoconjunctivitis.
(PubMed, Med Hypothesis Discov Innov Ophthalmol)
- "We compared the efficacies and safeties of 1% tacrolimus eye drops and 1% dexamethasone eye drops in managing unilateral shield ulcers and corneal epitheliopathy secondary to VKC. This suggests that tacrolimus could be administered as monotherapy for managing this debilitating ocular inflammatory condition. Further studies are required to determine the long-term safety and efficacy of this promising treatment modality."
Journal • Conjunctivitis • Dry Eye Disease • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology
March 07, 2025
COHOST: Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy
(clinicaltrials.gov)
- P1/2 | N=20 | Not yet recruiting | Sponsor: University of Nebraska | Initiation date: Jan 2025 ➔ May 2025
Trial initiation date • CNS Disorders • Movement Disorders • Parkinson's Disease
February 26, 2025
Post-operative Methylprednisolone Taper Course for Orthopedic Surgery
(clinicaltrials.gov)
- P4 | N=500 | Enrolling by invitation | Sponsor: Emory University | N=1000 ➔ 500 | Trial completion date: Jan 2025 ➔ Jan 2029 | Trial primary completion date: Jan 2025 ➔ Jan 2029
Enrollment change • Trial completion date • Trial primary completion date • Orthopedics
February 14, 2025
Accidental Discovery of Ocular Cicatricial Pemphigoid.
(PubMed, Cureus)
- "The patient was treated with oral corticosteroids, bolus cyclophosphamide, dexamethasone eye drops, and moisturizing agents. OCP is a systemic, progressive, and potentially blinding condition requiring early and multidisciplinary management to control inflammation and improve outcomes. However, it's frequently diagnosed late, especially in the absence of significant visual acuity loss, highlighting the need for increased clinical vigilance."
Journal • Cataract • Conjunctivitis • Dental Disorders • Dermatology • Fibrosis • Immunology • Inflammation • Keratitis • Ocular Inflammation • Ophthalmology
February 08, 2025
TLC- smartphone for ofloxacin and dexamethasone determination in pharmaceutical formulation and rabbit aqueous humor.
(PubMed, J Chromatogr B Analyt Technol Biomed Life Sci)
- "For KMnO4 visualization, the linearity was in the range of 10-50 μg/band for both drugs. The proposed method was validated following ICH guidelines, and was successfully applied for the estimation of ofloxacin and dexamethasone in their eye drop pharmaceutical form and rabbit aqueous humor."
Journal • Preclinical
January 24, 2025
Venetoclax Plus Inotuzumab for B-ALL
(clinicaltrials.gov)
- P1 | N=26 | Recruiting | Sponsor: Dana-Farber Cancer Institute | Trial primary completion date: Dec 2024 ➔ Dec 2025
Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22
January 23, 2025
N-acetylcysteine and chitosan conjugate modified dexamethasone nanostructured lipid carriers: Enhanced permeability, precorneal retention and lower inflammation for the treatment of dry eye syndrome.
(PubMed, Int J Biol Macromol)
- "Dexamethasone (Dex) is a primary medication for treating dry eye syndrome, and tobramycin-dexamethasone eye drops are commercially available. ELISA results showed a reduction in inflammation caused by dry eye. These findings suggest that CS-NAC@Dex-NLC is a promising vector for dry eye treatment, offering significant clinical relevance."
Journal • Corneal Abrasion • Dry Eye Disease • Inflammation • Ocular Inflammation • Ophthalmology
1 to 25
Of
194
Go to page
1
2
3
4
5
6
7
8